RIMAG GROUP (02522) surged over 8% in early trading. As of press time, the stock was up 7.64% to HK$18.74, with trading volume reaching HK$216 million. On the news front, on Wednesday Eastern Time, cardiac AI diagnostic company HeartFlow (HTFL.US), which went public just four days ago, saw its stock price peak at $33.24, representing a 74.9% increase from its $19 IPO price, achieving a market capitalization of $2.698 billion. On the same day, leading US medical imaging services provider RadNet (RDNT.US) also reached a new all-time high of $68.41, with a total market capitalization of $5.26 billion. As leading third-party medical imaging service providers in China and the US respectively, the outstanding performance of RadNet and HeartFlow provides highly valuable reference points for market evaluation of Hong Kong-listed companies in the same sector, particularly RIMAG GROUP. Analysis indicates that while RIMAG GROUP belongs to the same third-party medical imaging sector as RadNet and HeartFlow, it has carved out a differentiated development path through the simultaneous deployment of "traditional service sharing model + AI data ecosystem" within a single enterprise. The profit alert released on August 4th showed that RIMAG GROUP expects H1 2025 revenue of RMB 450-480 million, representing a year-on-year growth of 8.8%-16%; net profit of RMB 14.5-16.5 million, representing a dramatic year-on-year surge of 1350%-1550%. This marks the company's first interim high-growth performance since achieving profitability for the first time in 2023, signaling that traditional imaging services have gradually crossed the break-even point and representing the completion of the foundation for AI strategy commercialization takeoff.